Clinical trials: Ovarian Diseases
Polycystic Ovary Syndrome
The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women
This is a placebo controlled trial investigating the effect of 6 months atorvastatin 20mg/day therapy on androgens, glucose metabolism and inflammatory markers in women with PCOS.
- Trial name
- NCT01072097
- Testing
- Atorvastatin
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- University of Oulu
Ovarian Cancer, Adverse Effects
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Patients with early and advanced stages of epithelial ovarian cancer are treated with postoperative systemic chemotherapy after appropriate surgical staging and cytoreductive surgery.
- Trial name
- NCT01824615
- Testing
- Sunitinib
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Cathay General Hospital
Diminished Ovarian Reserve, Premature Ovarian Insufficiency
Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study
The investigators propose a pilot study to determine if autologous platelet-rich plasma (PRP) improves ovarian reserves and In-vitro fertilisation (IVF) outcomes in women with diminished ovarian reserve / premature ovarian…
- Conditions
- Diminished Ovarian Reserve, Premature Ovarian Insufficiency, Fertility Issues, IVF
- Trial name
- NCT05385848
- Testing
- Autologous Platelet-rich Plasma (PRP) Injection
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- KK Women's and Children's Hospital
Embryo Aneuploidies
Embryo Aneuploidies and Ovarian Stimulation
There is a considerable concern about the effects of controlled ovarian hyperstimulation (COH) for In Vitro Fertilization- Embryo Transfer (IVF-ET) on embryo quality and on the incidence of chromosomal abnormalities in oocytes…
- Trial name
- NCT00707525
- Testing
- Preimplantation Genetic Diagnosis
- Where
- Spain
- Volunteers
- healthy volunteers welcome
- Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
Ovarian Cancer
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional…
- Trial name
- NCT00179725
- Testing
- CC-5013, liposomal doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Celgene Corporation
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Infertility
Control Ovarian Stimulation Timing Test
IVF (in vitro fertilization) cycles fails more often than they succeed. Surprisingly very little effort is invested in defining the reasons for failure and possibly finding ways to improve the success on the next cycle.
- Trial name
- COST2 (NCT02397135)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Laval University
Ovarian Neoplasms
Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer
This is an observational prospective study. Patients diagnosed with advanced epithelial ovarian cancer (stage IC or higher) since 2008 will be asked to participate in this study by signing an informed consent.
- Trial name
- FindBRCANess (NCT02524808)
- Where
- 4 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Fundación de investigación HM
Ovarian Cancer
Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125
In 2015 the Danish Health authorities initiated major changes in the national follow-up (FU) program for ovarian cancer patients. The new FU program argues that there is no effect of routine monitoring of tumour marker CA125.
- Trial name
- NCT03004391
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Vejle Hospital
Ovarian Neoplasms
First-line Olaparib Combined With Bevacizumab Maintenance Therapy
Four phase III trials in ovarian cancer consistently showed that front-line poly(ADP-ribose) polymerase (PARP) inhibition can significantly improve progression-free survival.
- Trial name
- NCT05440578
- Testing
- olaparib plus bevacizumab maintenance therapy
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer
- Trial name
- NCT00003926
- Testing
- amifostine trihydrate, busulfan, filgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated…
- Trial name
- NCT07069335
- Testing
- Olaparib 150 MG
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Platinum-resistant Ovarian Cancer
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.
- Trial name
- NCT04718376
- Testing
- Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
- Where
- 7 sites in China
- Volunteers
- 56 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ovarian Cancer
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation.
- Trial name
- NCT06930755
- Testing
- NMS-03305293, Topotecan
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Nerviano Medical Sciences
Ovarian Cancer, Epithelial
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
This project is an open, single-center, prospective study aimed at developing high-sensitivity, high-specificity enrichment SERS chips using femtosecond laser processing technology.
- Trial name
- NCT06640348
- Testing
- No intervention
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Infertility
Protocols for Improved in Vitro Fertilization (IVF) Outcomes
Many infertile patients have a decreased chance of becoming pregnant when using in vitro fertilization (IVF). For these patients, many different treatments are available, but none of them have been shown to be better than the…
- Trial name
- NCT00334243
- Testing
- Microflare protocol for IVF, Antagonist protocol for IVF, Demi-halt protocol for IVF
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Premature Ovarian Insufficiency
Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells
investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under…
- Trial name
- alfarah (NCT06302543)
- Testing
- autologous bone marrow cells injection
- Where
- Iraq
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- abdulmajeed hammadi
Residual Tumor, Disease-free Survival
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
To assess the feasibility, Residual Tumor, complication rate and survival of totally laparoscopic primary cytoreduction in carefully selected patients with Advanced Ovarian Cancer, compared with abdominal primary cytoreduction in…
- Conditions
- Residual Tumor, Disease-free Survival, Overall Survival
- Trial name
- NCT02980185
- Testing
- Laparoscopic primary cytoreduction
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Università degli Studi dell'Insubria
Subfertility, Female, Ovulation Disorder
Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response
The management of the poor responder patients is very difficult. Currently, there is no any standard treatment for poor responder patients.
- Trial name
- NCT02940535
- Testing
- Diphereline (Triptorelin embonate), Decapeptyl (Triptorelin), human menopausal gonadotropin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Navy General Hospital, Beijing
Endometrial Carcinoma, Ovarian Carcinoma
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy…
- Conditions
- Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- AL3818 (NCT02584478)
- Testing
- AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 41 sites in United States, China and 4 more
- Volunteers
- 294 people
- Sponsor
- Advenchen Laboratories, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.